105 related articles for article (PubMed ID: 37841774)
1. Corrigendum to: Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience.
Gomerčić Palčić M; Matijaca H; Kruljac I; Vusić L; Hostić V; Vrbanić L; Mrsić F; Zrilić R; Ćelap I; Gaćina P
Biochem Med (Zagreb); 2023 Oct; 33(3):031201. PubMed ID: 37841774
[TBL] [Abstract][Full Text] [Related]
2. Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia - a single center experience.
Palčić Marija G; Hana M; Ivan K; Lucija V; Vedran H; Luka V; Mrsić F; Radovan Z; Ivana Ć; Petar G
Biochem Med (Zagreb); 2023 Jun; 33(2):020704. PubMed ID: 37324114
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of anticytokine treatments added to corticosteroids in patients with COVID-19-associated pneumonia and hyperinflammation: a single center experience.
Yildirim F; Erdogan M; Mutlu MY; Icacan OC; Onar MI; Bes C
Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7297-7304. PubMed ID: 36263542
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
Van den Eynde E; Gasch O; Oliva JC; Prieto E; Calzado S; Gomila A; Machado ML; Falgueras L; Ortonobes S; Morón A; Capilla S; Navarro G; Oristrell J; Cervantes M; Navarro M
Infect Dis (Lond); 2021 Apr; 53(4):291-302. PubMed ID: 33620019
[TBL] [Abstract][Full Text] [Related]
5. Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19.
Singla K; Puri GD; Guha Niyogi S; Mahajan V; Kajal K; Bhalla A
Cureus; 2022 Aug; 14(8):e28428. PubMed ID: 36176874
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Single and combined use of the platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and systemic immune-inflammation index in gastric cancer diagnosis.
Zhang J; Zhang L; Duan S; Li Z; Li G; Yu H
Front Oncol; 2023; 13():1200951. PubMed ID: 37483523
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
8. Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study.
Şener MU; Çiçek T; Öztürk A
Sao Paulo Med J; 2022; 140(5):627-635. PubMed ID: 35858016
[TBL] [Abstract][Full Text] [Related]
9. Corrigendum: Relationship between c-reactive protein/serum albumin ratio, neutrophil/lymphocyte ratio, and ANCA-associated vasculitis activity: A retrospective single center cohort study.
Tian Y; Liu N; Yin H; Duan L
Front Med (Lausanne); 2022; 9():963919. PubMed ID: 35957849
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
11. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia.
Valenzuela O; Ibáñez S; Poli MC; Roessler P; Aylwin M; Roizen G; Iruretagoyena M; Agar V; Donoso J; Fierro M; Montes J
Front Med (Lausanne); 2020; 7():596916. PubMed ID: 33304913
[No Abstract] [Full Text] [Related]
12. Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study.
Kardos Z; Szabó M; Baráth Z; Miksi Á; Oláh C; Kozma Á; Gergely JA; Csánky E; Szekanecz Z
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830885
[No Abstract] [Full Text] [Related]
13. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
Guaraldi G; Meschiari M; Cozzi-Lepri A; Milic J; Tonelli R; Menozzi M; Franceschini E; Cuomo G; Orlando G; Borghi V; Santoro A; Di Gaetano M; Puzzolante C; Carli F; Bedini A; Corradi L; Fantini R; Castaniere I; Tabbì L; Girardis M; Tedeschi S; Giannella M; Bartoletti M; Pascale R; Dolci G; Brugioni L; Pietrangelo A; Cossarizza A; Pea F; Clini E; Salvarani C; Massari M; Viale PL; Mussini C
Lancet Rheumatol; 2020 Aug; 2(8):e474-e484. PubMed ID: 32835257
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan.
Hassan M; Syed F; Zafar M; Iqbal M; Khan NU; Mushtaq HF; Badshah M
Cureus; 2021 Dec; 13(12):e20219. PubMed ID: 35004038
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study.
Zhang N; Zhang H; Tang Y; Zhang H; Ma A; Xu F; Sun Y; Jiang L; Shan F
Int J Med Sci; 2021; 18(4):921-928. PubMed ID: 33456349
[No Abstract] [Full Text] [Related]
18. Erratum: Prognostic Role of a New Inflammatory Index with Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase (CII: Colon Inflammatory Index) in Patients with Metastatic Colorectal Cancer: Results from the Randomized Italian Trial in Advanced Colorectal Cancer (ITACa) Study [Corrigendum].
Cancer Manag Res; 2020; 12():541. PubMed ID: 32021463
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
20. Sex-Dependent Performance of the Neutrophil-to-Lymphocyte, Monocyte-to-Lymphocyte, Platelet-to-Lymphocyte and Mean Platelet Volume-to-Platelet Ratios in Discriminating COVID-19 Severity.
Fors M; Ballaz S; Ramírez H; Mora FX; Pulgar-Sánchez M; Chamorro K; Fernández-Moreira E
Front Cardiovasc Med; 2022; 9():822556. PubMed ID: 35463770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
